ENOblock synergizes with colistin to treat Acinetobacter baumannii infections.
Irene Molina Panadero, Antonio Moreno Rodríguez, Aklani-Rose G.D. HIDALGO, Mercedes de la Cruz +10
AI summary
75% confidenceThis MES study investigates Acinetobacter baumannii, Drug Repurposing, ENOblock. The research focuses on system optimization and characterization.
Generated by MESSAI extraction pipeline · review against source PDF
Reported parameters
No values extracted from this paper yet.
No 3D model is mapped to this paper yet. Parameter ranges above still place reported values on the literature distribution.
Abstract
High-throughput screening studies provide an additional approach to discovering repurposed drugs for antimicrobial treatments. In this work, we report the identification of ENOblock, an anticancer drug, as an antimicrobial agent. We computationally and experimentally validated that ENOblock synergizes with colistin, the last resort antibiotic. Additionally, we identified enolase as the potential bacterial target for ENOblock. The in silico and in vitro antibacterial activity of ENOblock translated into potent in vivo efficacy in an animal infection model. Collectively, the preclinical data support the selection of ENOblock as a promising candidate for antimicrobial development, with the potential to address the urgent threat of infections caused by Acinetobacter baumannii.
Keywords
Identifiers
- PubMed
- 41174184
- Journal
- EMBO molecular medicine
- Year
- 2025